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doi:10.1016/j.jtcvs.2008.04.011Objective: Effects of timing of inception of amiodarone antiarrhythmic treatment after
corrective surgery for congenital heart defects are not yet well defined.
Methods: In a 10-year prospective observational study, 71 of 2651 patients (2885 pro-
cedures, 2106 bypass procedures) received amiodarone for newly detected postoper-
ative atrial (n5 70) or ventricular (n5 7) tachyarrhythmia: early treatment (initiation
within 60 minutes of arrhythmia detection) and late treatment (after that). From an in-
terim analysis, a treatment protocol was established (32 patients). Inotropic require-
ments were monitored, as were heart rate, blood pressure, central venous pressure,
and sedation requirements.
Results: With early treatment (n5 29), delay before start of amiodarone was 40.76
21.9 minutes, versus 227.76 228.1 minutes (P, .001) with late treatment (n5 42).
There were significant benefits of early treatment for times to rate (155.9 6 299.8 vs
407.6 6 376.9 minutes, (P , .001) and rhythm control (400.4 6 845 vs 1038.5 6
1158.4 minutes, P , .001), reduction in dose needed for rate control (28.2 6 45.2
vs 66.56 137.5 mg, P, .025), and significant reduction in pediatric cardiac intensive
care unit stay (3.326 1.9 vs 5.266 4.27 days, P, .01). There were continuous im-
provements in heart rate, blood pressure, and filling pressures without additional ino-
tropic requirements or side effects.
Conclusion: Early treatment of postoperative tachyarrhythmia with amiodarone
according to a standardized treatment protocol is safe and has beneficial effects on
arrhythmia control and pediatric cardiac intensive care unit stay.
A
variety of ventricular and supraventricular arrhythmias occur in pediatric
patients after corrective surgery for congenital heart defects. Patients admit-
ted to a pediatric coronary intensive care unit (PCICU) have a high incidence
of arrhythmias, most likely associated with their underlying pathophysiology and the
impact of the surgical intervention performed.1,2 In the early postoperative setting,
a transient low cardiac output syndrome is common.3 Many patients require transient
inotropic support with catecholamines, phosphodiesterase inhibitors, or both. Fre-
quently the tachyarrhythmias create hemodynamic instability, necessitating aggres-
sive management to allow beneficial outcome and to reduce ventilation times and
stay in the PCICU.4,5
Intravenous amiodarone hydrochloride has proved to be an effective antiarrhyth-
mic treatment option for various forms of tachyarrhythmia6-10 and is now included
in the treatment protocol of the advanced pediatric life support algorithm11 for malig-
nant ventricular arrhythmias. Despite the efficacy and good treatment success reported
in many case reports and smaller patient series, larger studies on the effects of early
treatment in this specific treatment group are missing. We present an analysis of the
effects of early and standardized treatment with amiodarone for postoperative tachy-
arrhythmias on rate and rhythm control as well as on PCICU stay.The Journal of Thoracic and Cardiovascular Surgery c Volume 136, Number 5 1215
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DAbbreviations and Acronyms
ANZPIC 5 Australian and New Zealand Paediatric
Intensive Care
JET 5 junctional ectopic tachycardia
PCICU 5 pediatric cardiac intensive care unit
Materials and Methods
This observational study collected data within the framework
of the Australian and New Zealand Paediatric Intensive Care
(ANZPIC) data-collection database. The retrospective chart review
was approved by the human research committee of the Prince
Charles Hospital Health Service District. We electronically searched
the computerized database containing all our pediatric intensive care
unit admissions for the 10-year period from July 1, 1995, until July
31, 2005, for patients who received amiodarone. In addition to the
data required for the purpose of the pediatric intensive care unit
quality management (ANZPIC database12), the use of amiodarone
was one of the additional selection criteria monitored prospectively
in our department. Patients who received amiodarone in the operat-
ing room, patients who were already receiving amiodarone treat-
ment before surgery, patients who received amiodarone as part of
measures during resuscitation, and patients without surgical inter-
vention were excluded from the analysis.
The diagnosis of arrhythmia was confirmed on the basis of clin-
ical notes, nursing observations in the charts, and independent
assessment of the electrocardiograms, including atrial electrocardio-
grams and electrocardiograms after the administration of adenosine
when available, by two experienced pediatric cardiologists and
pediatric intensivists (N.A.H. and C.K.C.). The first appearance of
the arrhythmia was defined as arrhythmia beginning, and the time
between the end of cardiopulmonary bypass and the admission to
the PCICU was calculated from that time.
Time of rate control of the tachyarrhythmia was defined as the
time at which the spontaneous pulse rate was first recorded at less
than 1 SD above the upper end of the reference range for heart
rate according to age. If external pacing was used, then the first re-
corded paced rate less than the value described was taken as the time
of rate control. Time of rhythm control of the tachyarrhythmia was
defined as the time at which sinus rhythm or successful atrial pacing
was documented in the chart.
For the analysis of the impact of the treatment beginning time,
treatment groups were divided into early and late treatment groups.
Early treatment was the beginning of amiodarone therapy within 60
minutes of first detection of the tachyarrhythmia. Late treatment was
the beginning of amiodarone therapy later than 60 minutes after the
first detection of the arrhythmia.
Acute adverse events were defined as malignant arrhythmia
requiring measures of resuscitation (catecholamine bolus dose or
cardiothoracic massage), higher grade atrioventricular block, and
most notably the occurrence of significant hypotension, defined as
a decrease in blood pressure of more than 20% of baseline before
treatment, necessitating a bolus dose of fluids for volume or bolus
administration of catecholamine (epinephrine). As part of the
department’s nursing protocol, these events should be clearly docu-
mented in the monitoring chart.1216 The Journal of Thoracic and Cardiovascular Surgery c NoTreatment
The management plan for treatment of the tachyarrhythmias was ini-
tially at the discretion of the attending intensivist. This included a re-
duction of catecholamines if possible, correction of biochemical
abnormalities, and intravenous infusion of amiodarone. In many
cases, a 5-mg/kg bolus dose of amiodarone was administered intra-
venously during the course of 1 to 4 hours, followed by continuous
infusion of amiodarone at a concentration ranging from 5 mg $ kg21
$min21 (7 mg $ kg21 $ d21) to 15 mg $ kg21 $min21 (21 mg $ kg21
$ d21). Because the Australian consultant system operates without
a consultant in pediatric intensive care or pediatric cardiology pres-
ent in the hospital on a 24-hour, 7-day basis, treatment of tachyar-
rhythmias was delayed in many circumstances until the definitive
diagnosis was established. During the last 3 years of the study, treat-
ment was formalized and changed according to a treatment protocol.
This protocol was initially developed for the treatment of junctional
ectopic tachycardia (JET) and later modified.13
Formal consultant approval before amiodarone therapy was not
required once the protocol was in place. The protocol included the
administration of amiodarone as a bolus dose of 5 mg/kg during
the course of 1 hour, followed by 1 or 2 further bolus doses of 5
mg/kg or by immediate intravenous infusion at 20 mg $ kg21 $
d21 until rate control was achieved. For the patient population,
rate control was determined as a heart rate below 160 beats/min or
1 SD above the upper end of the reference range for heart rate by
age in most cases. A reduction of the heart rate to 140 beats/min
was sought; the infusion was then tapered to 10 mg $ kg21 $ d21
for at least 24 hours (Figure 1). As part of our standard unit protocol,
all patients undergoing bypass surgery received atrial and ventricu-
lar pacing wires. As necessary or hemodynamically supportive,
atrial pacing was initialized to optimize atrioventricular synchrony.
Parameters
Patient characteristics were documented, and the age andweight data
were used for statistical analysis. The hemodynamic parameters of
heart rate, blood pressure, and central venous pressure were recorded
continuously in all patients admitted postoperatively. For the pur-
pose of this study, we used the values as documented in the chart
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Figure 1. Treatment protocol for postoperative tachyarrhythmia.
ECG, Electrocardiography; i.v., intravenously; iCa21, ionized cal-
cium current.vember 2008
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Dimmediately when the arrhythmia became clinically significant (data
set before treatment) and at 30minutes, 1 hour, and 2, 4, 8, 12, and 24
hours after the treatment with amiodarone (data sets at 30 minutes, 1
hour, 2 hours, 4 hours, 8 hours, 12 hours, and 24 hours). The cumu-
lative dose of amiodarone administered was calculated accordingly.
Assessment of Total Inotropic Dose
The doses of inotropes were analyzed according to the documentation
in the chart. For between-group comparisons, a total inotrope dosewas
calculated by adding the doses of dopamine and dobutamine inmicro-
grams per kilogram per minute and assigning an arbitrary equivalent
value of 0.1 mg $ kg21 $ min21 inotrope for each 0.1 epinephrine or
norepinephrine.14 In addition to that, an arbitrary equivalent value of
1 mg $ kg21 $ min21 inotrope was assigned to each 0.1 mg $ kg21 $
min21 milrinone. Data sets used were the same as for hemodynamic
parameters (data sets before treatment, 30 minutes, 1 hour, 2 hours,
4 hours, 8 hours, 12 hours, and 24 hours).
Assessment of Total Sedative Dose
Similar to the calculation of inotropic support, the doses of sedatives
and muscle relaxants were analyzed. For between-group compari-
sons, a total sedative dose was calculated by adding the doses of
morphine and midazolam in micrograms per kilogram per hour
(mg equivalent morphine) and assigning an arbitrary equivalent
value of 10 mg $ kg21 $ h21 sedative for each 1 mg $ kg21 $ h21
of fentanyl and an arbitrary equivalent value of 10 mg $ kg21 $
h21 sedative for each 1 mg $ kg21 $ h21 of propofol. When a para-
lytic agent was used, an additional arbitrary equivalent value of 10
mg $ kg21 $ h21 sedative was added. Data sets used were the same as
for hemodynamic parameters (data sets before treatment, 30 min-
utes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, and 24 hours).
Statistical Analysis
Statistical analyses were performed with SPSS version 14 software
(SPSS Inc, Chicago, Ill). Continuous variables are expressed as
mean6 SD (normally distributed data) or as median with interquar-
tile range (nonnormally distributed data). We tested for normal dis-
tribution of the data with the Kolmogorov–Smirnov test. Time
effects were evaluated with analysis of variance for normally distrib-
uted data and the Friedman test for nonnormally distributed data. In
case of significant time effects, the paired t test or the Wilcoxon test
was used to further specify these differences.
Results
Patients
A total of 2651 patients were admitted to the PCICU after car-
diac surgery. A total of 2885 procedures were performed,
with cardiopulmonary bypass used in 2106 cases. Of those
patients, a total of 71 fulfilled the inclusion criteria (2.46%).
General. The median age was 3 months, and the median
weight was 4.7 kg. Hemodynamically significant sinus
tachycardia was present in 3 patients, JET in 37, ectopic atrial
tachycardia in 10, intercurrent atrial flutter in 8, atrial fibrilla-
tion in 1, intra-atrial reentrant tachycardia in 1, ventricular ar-
rhythmias in 7, supraventricular tachycardia arising from
preexisting Wolff–Parkinson–White syndrome in 2, signifi-
cant atrial ectopic beats or runs in 4, and combinationsThe Journal of Thorathereof in 6 (Table 1). Arrhythmias were seen a median of
270 minutes after admission to the PCICU and a median of
390 minutes after cessation of cardiopulmonary bypass. A
5-mg/kg bolus dose of amiodarone was administered in 56
of 71 patients, followed by a continuous infusion of about
14 mg $ kg21 $ d21. Rate control was achieved 277 6 120
minutes after the beginning of the amiodarone treatment,
and rhythm control was achieved after 685 6 300 minutes
(median values; Table 2).
Subgroup analysis. Patient and arrhythmia characteris-
tics for the subgroups of early and late treatment are shown
in Tables 1 and 2. There were similar arrhythmias in the sub-
groups. The groups did not differ significantly with regard to
age and weight or as to the beginning of the arrhythmia.
There were statistically highly significant positive effects
on the times to rate and rhythm control and on the dose
required for rate control but not on the total duration and
dose of intravenous therapy. Most importantly, there was
a significant reduction in the PCICU stay, from 5.26 to
3.32 days.
Hemodynamics
Heart rate. There was an immediate reduction in heart
rate within the first hour after initial treatment; this became
TABLE 1. Patient characteristics
Total Early Late
Cohort selection
Total patients 2651
Procedures 2885
Bypass procedures 2106
Patients receiving
amiodarone
71
Arrhythmias
Sinus tachycardia 3 1 2
Junctional ectopic
tachycardia
37 15 22
Ectopic atrial
tachycardia
10 4 6
Intermittent atrial
flutter
8 6 2
Intermittent atrial
fibrillation
1 1 0
Ventricular
arrhythmias
7 2 5
WPWSVT 2 0 2
Significant atrial
ectopic beats
4 3 1
Combinations 6 3 3
Time frame was 10 years (July 1995–July 2005. Early, Group with treatment
within 60 minutes; late, group with treatment after 60 minutes; WPWSVT,
supraventricular tachycardia arising from preexisting Wolff–Parkinson—
White syndrome.cic and Cardiovascular Surgery c Volume 136, Number 5 1217
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DTABLE 2. Treatment characteristics
Early Late P value Significance
No. 29/71 42/71
Age (mo) 13.3 6 29.6 18.7 6 38.5 .637 NS
Weight (kg) 7.0 6 6.0 9.4 6 14.5 .574 NS
Time after pump (min) 579.8 6 669.2 1099 6 1544.3 .155 NS
Time after admission (min) 458.8 6 621 927.8 6 1480 .183 NS
Time to treatment (min) 40.7 6 21.9 227.7 6 228.1 ,.001 ,.001
Amiodarone bolus dose (No.) 23/29 (79.3%) 34/42 (80.1%) .875 NS
Pacing (No.) 12/29 (41.9%) 15/42 (35.8%) .804 NS
Time to rate control (min) 155.9 6 299.8 407.6 6 376.9 ,.001 ,.001
Time to rhythm control (min) 400.4 6 845 1038.5 6 1158.4 ,.001 ,.001
Dose at rate control (mg) 28.2 6 45.2 66.5 6 137.5 .013 ,.025
Total time of intravenous therapy (h) 44.9 6 40.3 57.4 6 35.8 .067 NS
Total intravenous dose (mg) 247.4 6 495.3 253.6 6 407.3 .808 NS
Pediatric intensive care unit stay (d) 3.32 6 1.9 5.26 6 4.27 .01 ,.01
All values are mean6 SD except numbers of patients as marked. Early, Group with treatment within 60 minutes; Late, group with treatment after 60 minutes;
NS, not significant.statistically significant at 30 minutes (Figure 2). There was,
however, no statistically significant difference in heart rate
between the subgroups. Pacing was used in 12 of 29 patients
(41.9%) in the group with early treatment and in 15 of 42
(35.8%) in the group with late treatment (difference not
significant).
Mean arterial pressure. There was a continuous increase
in the mean arterial pressure after the administration of amio-
darone (Figure 3) that was statistically significant at 4 hours
after the start of treatment. There was, however, no statisti-
cally significant difference between the subgroups.
Central venous pressure. There was a continuous but
slight decrease in the central venous pressure after the admin-
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Figure 2. Time courses of heart rate in early treatment group (gray
crosses) and late treatment group (black circles). There were sig-
nificant time effects (P < .001 by analysis of variance). No signif-
icant differences between study groups were observed. Data
points represent mean; error bars indicate SD.1218 The Journal of Thoracic and Cardiovascular Surgery c Nistration of amiodarone, from 11.96 2.9 mmHg before treat-
ment to 10.26 2.6 mm Hg at 12 hours and 9.56 2.4 mm Hg
at 24 hours. There was, however, no statistically significant
difference between the subgroups.
Drug Requirements
Amiodarone dose used. The cumulative amiodarone
doses used were about 5.1 6 6.5 mg/kg at 120 minutes after
the beginning of the treatment and 8.76 9.6 mg/kg at 4 hours
(Figure 4). There was, however, no statistically significant
difference between the subgroups.
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Figure 3. Time courses of mean arterial pressure in early treat-
ment group (gray crosses) and late treatment group (black cir-
cles). There were significant time effects (P < .001 by analysis
of variance). No significant differences between study groups
were observed. Data points represent mean; error bars indicate
SD.ovember 2008
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DSedation. With the sedation score used, we could not
demonstrate any statistically significant or clinically relevant
reduction in the cumulative dose of sedatives used within the
initial 12 hours after initial amiodarone treatment. Only at 24
hours after the beginning of amiodarone administration was
a significant reduction in sedatives achieved. The mean seda-
tion scores were 26.46 8.6 before treatment, 25.36 6 at 12
hours after treatment, and 18.76 5.2 at 24 hours. There was
no statistically significant difference between the subgroups.
Inotropic requirements. With the inotrope score used, at
no time could we demonstrate a statistically significant or
clinically relevant increase in the cumulative dose of ino-
tropes used. The mean inotropic score was 8.96 1.7) before
initial amiodarone treatment, declining to 7.4 6 1.2 at 12
hours and 5.5 6 1.5 at 24 hours. Again, there was no statis-
tically significant difference between the subgroups.
Adverse Events
We could not detect in either treatment group any adverse
events necessitating additional catecholamine therapy, the
administration of additional fluid bolus doses, or resuscita-
tion measures.
2nd  Amiodarone bolus at 5 mg/kg over 60 mins iv.
Reassess diagnosis and rate every 2 hrs
Reassess diagnosis and rate every 2 hrs
3rd  Amiodarone bolus at 5 mg/kg over 60 mins i.v.
Postoperative tachyarrhythmia
Confirm diagnosis: 6(12) lead ECG, atrial ECG,
adenosine
1st Amiodarone bolus at 5 mg/kg over 60 mins i.v.
- temperature - normalise
- potassium - aim for 4-4.5 mmol/l
- calcium - normal iCa2+
- magnesium - >1.5-2 mmol/l, bolus of 1 mmol/kg
- pacemaker - optimize, VVI backup
- catecholamines - decrease if possible
If
haemodynamically
unstable -> start
Amiodarone
infusion
at
20 mg/kg/day
Rate/rhythm control achieved
start an amiodarone  infusion at 10 mg/kg/day
Figure 4. Time courses of cumulative amiodarone dose in early
treatment group (gray crosses) and late treatment group (black cir-
cles). There were significant time effects (P < .001 by Friedman
test). No significant differences between study groups were
observed. Data points represent mean; error bars indicate SD.The Journal of ThorDiscussion
This was an observational study of continuously collected
data within the framework of the prospective ANZPIC data
collection.12 We investigated the effects of timing of therapy
with intravenous amiodarone in the early postoperative
setting in infants and children immediately after corrective
or palliative cardiac surgery. To our knowledge, this is the
largest study evaluating the beneficial effect of early treat-
ment with amiodarone in this setting. After analysis of the
data, there were a number of important findings.
Timing of Amiodarone Treatment
The administration of amiodarone resulted in a significant
and beneficial reduction in the heart rate, facilitating rapid
rate and then rhythm control without significant side effects.
Adequate rate and rhythm controls are important keystones in
postoperative management, because the reduction of heart
rate reduces oxygen demands and may facilitate atrial pacing
and enable adequate diastolic filling, thereby affecting pre-
load and cardiac output.2,15-17 Patients admitted to a PCICU
have a high incidence of tachyarrhythmia, most likely associ-
ated with the underlying pathophysiology.1,2 Tachyarrhyth-
mia, especially atrial fibrillation, is relatively common in
adults after coronary artery bypass grafting, leading to signif-
icant morbidity including hypotension, heart failure, throm-
boembolic complications, prolonged hospital stay, and
increased hospital costs. Prophylactic administration of
amiodarone has been shown to be safe, and effective and
hemodynamically well tolerated, even in patients with
reduced left ventricular function.18-22
In our population, the administration of amiodarone re-
sulted in a significant and beneficial reduction in the heart
rate, facilitating rapid rate and then rhythm control. On the
basis of our analysis and the definitions we used, we could
not detect any significant side effects, such as malignant ar-
rhythmia and, most notably, significant hypotension.
Not all the patients received an amiodarone bolus dose;
this variation was initially related to the management plans
of the attending consultant intensivists. The overall accep-
tance of bolus administration increased when the standard-
ized treatment protocol of a ‘‘slow’’ bolus administration of
5 mg/kg during the course of at least 1 hour was imple-
mented. There was, however, no significant difference in
the initial dose of amiodarone administered that could ex-
plain the treatment results (Figure 4). In our analysis of the
study group that divided the patients into two subgroups
(early treatment, within 60 minutes after start of tachyar-
rhythmia, and late treatment, after 60 minutes), we have dem-
onstrated a beneficial effect of early treatment with regard to
rate and rhythm control. There were only small differences in
absolute heart rate, but this may be explained by the relatively
high percentage of patients receiving atrial pacing as a treat-
ment standard (especially for patients with JET).acic and Cardiovascular Surgery c Volume 136, Number 5 1219
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DAdditionally, we found a reduction in the amiodarone
dose needed for rate control, whereas the total dose applied
intravenously and the total duration of intravenous treatment
were not different. Most importantly, we demonstrated a sig-
nificant reduction in PCICU stay.
Heart Rate and Rhythm
We could not discern significant differences between the
treatment groups with regard to absolute heart rate at any
given point. There was, however, a significant difference in
the success rate of treatment as defined. We believe this
was an artifact of the relatively high percentage of patients re-
ceiving atrial pacing as a treatment standard; this pacing may
have altered the actual heart rate achieved, thus explaining
the relatively small differences in absolute rate. There was
no statistically significant difference in the rate of pacing
between the groups (Table 2).
Proarrhythmic reactions to amiodarone and the induction
of other acute tachyarrhythmias, especially in patients with
prolongation of the QT interval as well as significant brady-
cardia or atrioventricular block, have been described.23-27 In
our patient group, no additional arrhythmogenic effects were
noticed before hospital discharge. These results are similar
to those of other studies in children, which also have not
demonstrated any significant arrhythmogenic potential of
amiodarone but have reported excellent success rates.
Amiodarone can induce sinus bradycardia, sinus arrest, and
asystole, especially when used with digoxin, calcium-chan-
nel antagonists, or b-blockers. In the early studies from the
Texas Children’s Hospital, some patients with atrial flutter
had severe bradycardia develop, necessitating pacemaker im-
plantation.28
Positive effects were reported by Laird and colleagues,8
who treated 11 patients with postoperative JET with
a mean bolus dose of 8.2 mg/kg intravenous amiodarone.
Mean heart rate decreased from 202 to 147 beats/min, and
mean systolic blood pressure increased from 64 to 88 mm
Hg. Similar effects have been reported in the setting of atrial
flutter, repetitive atrial ectopic beats, paroxysms of supraven-
tricular tachycardia, and other forms of supraventricular and
ventricular arrhythmia in children.6,7,29-33 With the doses and
treatment protocol used, we did not see any atrioventricular
block, but we did see a significant and beneficial reduction
in heart rate.
Three patients after introduction of the treatment protocol
had sinus tachycardia as an underlying arrhythmia, 1 in the
late treatment group and 2 in the early group. In all 3 cases,
other arrhythmias were present simultaneously. We therefore
did not demonstrate unnecessary treatment with our protocol.
Hemodynamic Stability
Tachyarrhythmia often induces hemodynamic instability in
patients like ours, necessitating aggressive hemodynamic
support. On the basis of the inotropic score necessary to ob-1220 The Journal of Thoracic and Cardiovascular Surgery c Notain adequate hemodynamics, a postoperative low–cardiac
output syndrome can be presumed in our patients. Despite
this, the inotropic support required could be decreased in
both early and late treatment groups, with significant im-
provement in blood pressure and filling pressures after amio-
darone treatment. Amiodarone is known to have significant
side effects; these include especially profound hypotension
shown in animals and reported in adults, vasodilatation, neg-
ative inotropic effects, and significant bradycardia, especially
when administered intravenously.6,10,34-36 Reports on the ad-
ministration of amiodarone in the early postoperative setting
in children are scarce. In the literature on infants and children
to date, many studies have reported only minimal hypoten-
sive side effects.7,8 A prospective, randomized, multicenter
study of 67 pediatric patients, however, revealed a high rate
(mean 36%) of significant hypotension after rapid bolus ad-
ministration of amiodarone, and this effect was dose depen-
dent.9 Special caution is warranted when treating patients
with decreased contractility and end-stage heart failure, and
cases of cardiovascular collapse have been reported.37 With
a slow bolus administration of amiodarone during the course
of at least 60 minutes followed by a continuous infusion with
10 to 20 mg $ kg21 $ d21, our protocol proved to be safe in
the early postoperative setting without necessitating addi-
tional inotropic support. In all cases, treatment initiation
with amiodarone was followed about 24 hours later by a re-
duction in sedation because of hemodynamic stability and in
preparation for weaning and extubation.
Limitations of the study
This study has important limitations. First, it is a single-
center, uncontrolled, cohort study of pediatric subjects with
postoperative arrhythmias treated with amiodarone. Our
provocative but statistically significant results may require
validation in a larger, and perhaps randomized, prospective
trial. Even though the data analysis was performed retrospec-
tively, data acquisition was continuous and prospective in
accordance with the prospective and continuous ANZPIC
data collection.
One might argue that one of the most important limita-
tions of our study is the lack of effective blinding in this
observational investigation, which may have led to a thera-
peutic bias. Nevertheless, the therapeutic intervention was
guided not by the specific amiodarone treatment protocol
but by the hemodynamic and other clinical needs of the
patients. Other protocols within the unit, especially those
that may have had an influence on the results of this study
(extubation policies, discharge criteria, catecholamine use,
sedation strategies, etc) did not change substantially during
the period described. This is especially important with regard
to the discharge policies for patients requiring amiodarone
treatment and their transfer from the PCICU to a step-
down unit (high-dependency unit or cardiology ward). Other
confounding variables that may have contributed to thesevember 2008
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Dresults, such as changes with time in surgical techniques,
anesthetic treatment, and bypass management, cannot be
excluded.
A number of additional patient-related factors could result
in systematic differences in time to treatment, including gen-
eral hemodynamic status. We did not, however, detect any
significant difference in catecholamine requirements, as ex-
pressed by the catecholamine score, nor in the baseline blood
pressure and other hemodynamic factors. Clearly, there was
a trend toward concentration of the patients receiving early
treatment in the more recent period (including use of the
treatment protocol) and of the patients receiving late treat-
ment in the earlier years. In analysis of these subgroups, how-
ever, no clinically relevant differences were evident; that is,
early treatment even at the beginning of the study was asso-
ciated with significantly better results than was late treatment.
On the basis of available data, the only major factor that ap-
pears to have influenced the outcome in these patients was the
early treatment of arrhythmia with amiodarone.
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